THE PROBLEM: A medtech start-up with a leading CE-marked product faced a strategic resource allocation decision: invest in next-generation technology in the current low-growth market, or place bets on riskier technologies in the emerging higher growth segment? THE SOLUTION: RNA undertook a comprehensive strategic and commercial operations review, including market segmentation, competitive analysis, assessment of